Moreover, luteolin shows anticancer potential against colorectal cancer (CRC) cells by modulating PTN via miR-384 expression suggesting that PTN may serve as a valuable candidate for therapeutic applications in CRC treatment [121]. This evidence concerns the gene PTN and colorectal carcinoma.